Colorectal surgery

PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023

Retrieved on: 
Monday, October 9, 2023
SHIELD, Large intestine, Colorectal surgery, American College, Pharmaceutical industry

PETACH TIKVA, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that SHIELD I Phase 3 clinical data for D-PLEX100 will be highlighted in a presentation at the American College of Surgeons Clinical Congress 2023, to be held on October 22-25, 2023, in Boston, MA.

Key Points: 
  • PETACH TIKVA, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that SHIELD I Phase 3 clinical data for D-PLEX100 will be highlighted in a presentation at the American College of Surgeons Clinical Congress 2023, to be held on October 22-25, 2023, in Boston, MA.
  • Impact of Locally Applied Doxycycline-Eluting Drug (D-PLEX) on Incisional Infection Rate in Elective Colorectal Surgery: A Phase 3, Prospective, Randomized, Double-Blind, Multicenter, and Multinational Clinical Trial

FluidAI Medical Announces $15M in Series A Funding for AI-Driven Postoperative Monitor at HLTH 2023

Retrieved on: 
Tuesday, October 10, 2023
Surgery, Health, Death, Bleeding, Government, AI, Sepsis, Mortality, Wound healing, Artificial intelligence, Patient, Trust, Patient safety, Fungal infection, SOSV, Surgeon, Medtech, Disability, Colorectal surgery, Infection, Hospital, Nursing

MedTech FluidAI Medical secures funding to empower healthcare providers with data-driven insights to transform postoperative care.

Key Points: 
  • MedTech FluidAI Medical secures funding to empower healthcare providers with data-driven insights to transform postoperative care.
  • Following any surgical intervention, there are inherent risks of adverse outcomes, irrespective of how minor or major the procedure may be.
  • At FluidAI, our goal is to continuously push the boundaries of what's possible in postoperative care, ensuring patients recover safely and quickly.
  • "With FluidAI, surgeons can ensure better clinical outcomes, shorter hospital stays for patients, and cost efficiencies across the healthcare ecosystem.

Lipogems® Announces 140 independent Peer Reviewed Publications with 5 years of follow up in orthopaedics

Retrieved on: 
Friday, September 22, 2023
Science, Colorectal surgery, General surgery, FDA, Publication, Arthroscopy, Physician, Patient, Evidence-based medicine, Dentistry

ATLANTA, Sept. 22, 2023 /PRNewswire/ -- Lipogems announced today that there are now 140 peer reviewed publications supporting Lipogems' MicroFat with 5 years of follow up in orthopaedics.

Key Points: 
  • ATLANTA, Sept. 22, 2023 /PRNewswire/ -- Lipogems announced today that there are now 140 peer reviewed publications supporting Lipogems' MicroFat with 5 years of follow up in orthopaedics.
  • "Lipogems has sought out to help patients that have tried conservative options and other therapies with limited relief.
  • "The gold standard for evidence is 1 year follow up and we are excited to report 5 years follow up with positive results after a single injection of MicroFat."
  • "Many physicians have patients that have exhausted other therapies and they don't have many options to help them.

Lipogems® Announces 140 independent Peer Reviewed Publications with 5 years of follow up in orthopaedics

Retrieved on: 
Thursday, September 21, 2023
Science, Colorectal surgery, General surgery, FDA, Publication, Arthroscopy, Physician, Patient, Evidence-based medicine, Dentistry

ATLANTA, Sept. 21, 2023 /PRNewswire/ -- Lipogems announced today that there are now 140 peer reviewed publications supporting Lipogems' MicroFat with 5 years of follow up in orthopaedics.

Key Points: 
  • ATLANTA, Sept. 21, 2023 /PRNewswire/ -- Lipogems announced today that there are now 140 peer reviewed publications supporting Lipogems' MicroFat with 5 years of follow up in orthopaedics.
  • "Lipogems has sought out to help patients that have tried conservative options and other therapies with limited relief.
  • "The gold standard for evidence is 1 year follow up and we are excited to report 5 years follow up with positive results after a single injection of MicroFat."
  • "Many physicians have patients that have exhausted other therapies and they don't have many options to help them.

Tampa General Hospital Named "Best in Class" by WebMD Choice Awards

Retrieved on: 
Wednesday, September 20, 2023
WebMD, U.S. News & World Report Best Hospitals Rankings, Hospital, Perception, Colorectal surgery, Stomach cancer, GERD, U.S. News & World Report, Patient, Practitioner, Physician, Sleep disorder, Tampa General Hospital, TGH, Neurology, News, Nursing, Orthopedic surgery

TAMPA, Fla., Sept. 20, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) earned top honors in this year's WebMD Choice Awards. The academic health system is one of 26 health systems across the nation to receive the WebMD Elite Choice Award, which honors systems that patients and providers prefer 2:1 over competitors.

Key Points: 
  • TAMPA, Fla., Sept. 20, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) earned top honors in this year's WebMD Choice Awards.
  • "This national recognition by patients and providers as the region's preferred hospital is a testament to the exceptional care we offer at Tampa General Hospital," said John Couris, president and CEO of Tampa General.
  • In 2023, WebMD honored 167 health systems, and 26 recipients earned the WebMD Elite Choice Award, including Tampa General.
  • The WebMD recognition comes just weeks after Tampa General was named the #1 hospital in Tampa Bay by the 2023-2024 U.S. News & World Report's Best Hospitals , an honor TGH has earned for six consecutive years.

The Joint Commission announces new chief innovation officer

Retrieved on: 
Monday, July 17, 2023
Joint Commission, Accreditation, University Hospitals Cleveland Medical Center, MSHA, Doctor of Philosophy, MACP, Colorectal surgery, Certification, Agency for Healthcare Research and Quality, Baldwin Wallace University, MD, Patient safety, Press Ganey Associates, Knowledge, General surgery, Case Western Reserve University School of Medicine, Joint, AHRQ, Health, Safety, Management, Medical device, Nursing, Cleveland Clinic

Dr. Merlino brings a wealth of knowledge and expertise to spearhead The Joint Commission's vision for evidence-based, data-driven, and outcomes-oriented health care.

Key Points: 
  • Dr. Merlino brings a wealth of knowledge and expertise to spearhead The Joint Commission's vision for evidence-based, data-driven, and outcomes-oriented health care.
  • As chief innovation officer, Dr. Merlino will provide day-to-day focus on the transformation of The Joint Commission’s services; utilizing data and innovation to inform strategic initiatives which advance health care quality and safety worldwide.
  • Dr. Merlino currently serves as chief clinical transformation officer at Cleveland Clinic, overseeing enterprise strategy, business development, safety, quality, and patient experience.
  • "Jim’s appointment marks a significant milestone for our organization, as we welcome a visionary and effective leader in patient-centered innovation in quality and safety,” says Jonathan B. Perlin, MD, PhD, MSHA, MACP, FACMI, president and chief executive officer, The Joint Commission Enterprise.

Virtual Incision Announces MIRA’s Clinical Trial Results Will Be Presented at the 2023 ASCRS Scientific Meeting

Retrieved on: 
Wednesday, May 31, 2023
Technology, FDA, Health, Robotics, Health Technology, Medical Devices, Research, Surgery, Science, Hardware, Clinical Trials, Investigational device exemption, Surgeon, De novo, Marketing, Main Line Health, Clinical trial, Lankenau Medical Center, ASCRS, Lankenau Institute for Medical Research, American Society of Colon and Rectal Surgeons, Colorectal surgery, Hospital, RAS, MIRA, IDE, Society, Medical research, Safety, Dentistry

Virtual Incision Corporation , the developer of the world’s first miniaturized robotic-assisted surgery (RAS) system, today announced that the data from its Investigational Device Exemption (IDE) clinical trial will be presented at the 2023 American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting in Seattle, WA.

Key Points: 
  • Virtual Incision Corporation , the developer of the world’s first miniaturized robotic-assisted surgery (RAS) system, today announced that the data from its Investigational Device Exemption (IDE) clinical trial will be presented at the 2023 American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting in Seattle, WA.
  • The study was designed to evaluate the safety and efficacy of MIRA for use in bowel resection procedures.
  • John Marks will unveil the full patient data set to his peer group for the very first time,” said John Murphy, president and chief executive officer of Virtual Incision.
  • Virtual Incision is the first RAS developer to complete a U.S. IDE study to support a De Novo request in bowel resection.

WellSpan York Hospital achieves Center of Excellence in Robotic Surgery accreditation

Retrieved on: 
Monday, April 24, 2023
Diamond, Surgeon, South Central Pennsylvania, Accreditation, Education, SRC, WellSpan Health, Gynaecology, Colorectal surgery, Patient, Risk, General surgery, Hospital, Roger Hawkins (drummer), Elective surgery, Healthcare Facilities Accreditation Program, Urology, Nursing, Dentistry

York, Pa., April 24, 2023 (GLOBE NEWSWIRE) -- WellSpan York Hospital is among an elite group of robotic-assisted surgical centers in Pennsylvania, having achieved accreditation as a Center of Excellence in Robotic Surgery from Surgical Review Corporation (SRC), a nonprofit patient safety organization.

Key Points: 
  • York, Pa., April 24, 2023 (GLOBE NEWSWIRE) -- WellSpan York Hospital is among an elite group of robotic-assisted surgical centers in Pennsylvania, having achieved accreditation as a Center of Excellence in Robotic Surgery from Surgical Review Corporation (SRC), a nonprofit patient safety organization.
  • Robotic surgery spans multiple specialties, including gynecology, gynecologic oncology, urology, urogynecology, bariatric, thoracic, colorectal, and general surgery.
  • “Earning this accreditation signifies our commitment to excellence and to providing high quality, safe and effective surgical care that matches the skills of our expert clinicians,” says Victoria Diamond, senior vice president, WellSpan Health Central Region, and president, WellSpan York Hospital.
  • “This accreditation signals that this facility is among the best in this specialty and is dedicated to delivering the highest level of care possible.”
    In addition to WellSpan York Hospital achieving the Center of Excellence in Robotic Surgery accreditation, six surgeons at the hospital have gone above and beyond to achieve the designation of Master Surgeon in Robotic Surgery from SRC.

Versius used to perform over 10,000 cases

Retrieved on: 
Monday, March 27, 2023
CE, Hospital, Surgeon, Endoscopic thoracic sympathectomy, Lung lobectomy, Colectomy, Colorectal surgery, Cardiothoracic surgery, Patient, IDEAL, Hernia, General surgery, CMR, GI, CMR Surgical, Safety, BST, Dentistry

CMR Surgical (CMR) – the global surgical robotics business – today announces that its next-generation surgical robotic system, Versius®, has been used to perform more than 10,000 soft tissue surgical cases in hospitals around the world.

Key Points: 
  • CMR Surgical (CMR) – the global surgical robotics business – today announces that its next-generation surgical robotic system, Versius®, has been used to perform more than 10,000 soft tissue surgical cases in hospitals around the world.
  • The surgical cases span 130 complex and benign procedure types across seven surgical specialties including colectomies, hysterectomies, hernia repairs and lobectomies.
  • Versius was developed to expand availability to minimal access surgery around the world.
  • The system gained CE approval in 2019 and today there are over 100 Versius systems installed globally.

Governor McMaster Declares March "SC Zero Harm Patient Safety Month"

Retrieved on: 
Monday, March 13, 2023
Policy, Memorial Hermann Health System, Methicillin-resistant Staphylococcus aureus, Hip, Learning, DMH, Blue Cross Blue Shield Association, Mental health, Culture, Patient safety, Colorectal surgery, National Patient Safety Agency, Workforce, Patient, Clostridioides, Clostridioides difficile, Safety, MRSA, Suicide, Infection, Partnership, DHEC, Nursing

COLUMBIA, S.C., March 13, 2023 /PRNewswire/ -- In recognition of the strides of South Carolina's hospitals and health systems in advancing care quality and patient safety, Governor McMaster has declared March "SC Zero Harm Patient Safety Month."

Key Points: 
  • COLUMBIA, S.C., March 13, 2023 /PRNewswire/ -- In recognition of the strides of South Carolina's hospitals and health systems in advancing care quality and patient safety, Governor McMaster has declared March "SC Zero Harm Patient Safety Month."
  • SCHA has awarded more than 1,500 Certified Zero Harm Awards since launching the program in 2013.
  • In recent years the state's hospital community has expanded the scope of Zero Harm to include suicide prevention with the Drive to Zero Suicide award.
  • The Certified Zero Harm awards are administered by SCHA thanks to the support of BlueCross BlueShield of South Carolina.